Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 288 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Peak Bone Mass

NCT01301183
Conditions
Anorexia Nervosa
Interventions
RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
Interventions
FACT-B, Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen, Archived tissue collection
Behavioral · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
70 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
fulvestrant, anastrozole
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
856
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

NCT00115024
Conditions
Atherosclerosis, Postmenopause
Interventions
Micronized 17B-estradiol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
46 Years to 80 Years · Female only
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 1998
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Asymptomatic Microscopic Hematuria
Interventions
Estradiol Ring
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Suicidal Ideation
Interventions
Transdermal Estradiol + Placebo, Oral Micronized Progesterone + Placebo, Placebos
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Recurrent Urinary Tract Infection
Interventions
Periurethral application of estradiol cream, Intravaginal application of estradiol cream
Drug
Lead sponsor
Stephanie Wang Zuo
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Cranberry Township, Pennsylvania • Erie, Pennsylvania • Pittsburgh, Pennsylvania
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

NCT03568708
Conditions
Primary Ovarian Insufficiency
Interventions
Transdermal Estrogen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Estrogen on Fear Extinction R61

NCT02673606
Conditions
Fear, Fear; Examination, Phobic
Interventions
Estradiol 2Mg Tablet, Estradiol 4Mg Tablet, Placebo Pills
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Bone Mass Accrual in Adolescent Athletes

NCT00827151
Conditions
Amenorrhea, Bone Loss
Interventions
Estrogen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 21 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 2 Interventional Results available

Estrogen for Triple Negative Breast Cancer

NCT01083641
Conditions
Female Breast Cancer
Interventions
Estradiol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Prostate Cancer
Interventions
Premarin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Research Investigation of Soy and Estrogen

NCT00997893
Conditions
Menopause, Hot Flashes
Interventions
Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo
Dietary Supplement · Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Conditions
Eating Disorders, Hypoestrogenemia
Interventions
17-β estradiol transdermal patches, Placebo Patch, Micronized progesterone 200 MG, Placebo Pill.
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer
Interventions
Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Congenital Adrenal Hyperplasia (CAH)
Interventions
Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Phase 2 Interventional Results available

Palbociclib After CDK and Endocrine Therapy (PACE)

NCT03147287
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Avelumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
22
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 18 more
Conditions
Menopause
Interventions
bioidentical hormone (Biest), bioidentical hormone (Vivelle-Dot)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

Treatment of Prepubertal Labial Adhesions

NCT02218463
Conditions
Prepubertal Labial Adhesions
Interventions
Estradiol cream 0.01%, Cetaphil
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 12 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Early Phase 1 Interventional Accepts healthy volunteers

Estrogen Hormone Products

NCT05645406
Conditions
Menopause
Interventions
Divigel 0.1% Topical Gel, Compounded estradiol product
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions
NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 16 more
Conditions
Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions
Estradiol or Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Temple, Texas